Skip to main content
Zelluna ASA logo

Zelluna ASA — Investor Relations & Filings

Ticker · ULTI ISIN · NO0010851603 LEI · 254900B4VALJZR9TL744 OL Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2025-03-26 Share Issue/Capital Cha…
Country NO Norway
Listing OL ULTI

About Zelluna ASA

https://www.zelluna.com/

Zelluna ASA is a cell therapy company pioneering the development of T cell receptor (TCR) guided natural killer (NK) cell immunotherapies for the treatment of solid cancers. The company's proprietary TCR-NK platform is designed to combine the high-precision targeting of TCRs with the potent, innate anti-tumor activity of NK cells. This approach aims to overcome the challenges associated with treating solid tumors. Zelluna is focused on creating a new generation of allogeneic, "off-the-shelf" cell therapies. The mission is to deliver transformative and potentially curative treatments for patients with advanced solid cancers, addressing a significant unmet medical need.

Recent filings

Filing Released Lang Actions
Zelluna ASA [ZLNA]: Notification of transaction by close associate of primary insider
Share Issue/Capital Change Classification · 99% confidence The document is a notification regarding a transaction involving shares of Zelluna ASA. Specifically, it details that 'Radforsk Investeringsstiftelse, a close associate of chair of the board of directors and primary insider of the Company, Anders Tuv, has today subscribed for seven (7) new shares'. This describes an insider/related party transaction concerning company shares. This aligns directly with the definition of 'Director's Dealing' (Code: DIRS), which covers reports of personal share transactions by company directors and executives (insider trades), extended here to close associates of primary insiders. Although it mentions a capital increase resolution, the core content is the notification of the resulting subscription by the insider's associate, making DIRS the most precise fit over Capital/Financing Update (CAP) or Share Issue/Capital Change (SHA). The document length is short (2458 chars), but it is a direct notification of a transaction, not an announcement of a report's publication.
2025-03-26 English
Zelluna ASA [ZLNA]: Share capital increase resolution
Share Issue/Capital Change Classification · 99% confidence The document is a short announcement from Zelluna ASA dated March 26, 2025, titled 'Share capital increase resolution'. It details the issuance of seven new shares following a prior resolution for a reverse share split. This action directly relates to changes in the company's capital structure (issuance of new shares). Based on the definitions, 'Capital/Financing Update' (CAP) is the most appropriate category for announcements regarding share issuance and capital structure changes. The document length (2404 chars) is short, but it is the primary announcement of the event, not just a notice that a report is attached, making CAP more specific than RPA or RNS.
2025-03-26 English
Ultimovacs ASA: Approval and publication of prospectus
Report Publication Announcement Classification · 98% confidence The document is a short announcement (1992 characters) titled 'Ultimovacs ASA: Approval and publication of prospectus'. It explicitly states that a prospectus has been approved by the Financial Supervisory Authority of Norway and will be made available on their website. This fits the definition of a Report Publication Announcement (RPA) because it announces the availability of a formal document (the prospectus) rather than being the prospectus itself. It is not a standard regulatory filing like 10-K or IR, nor does it relate to dividends, management changes, or earnings. The key phrase is the announcement of the 'publication of prospectus'.
2025-02-28 English
Ultimovacs ASA: Cancellation of subsequent repair offering
Share Issue/Capital Change Classification · 99% confidence The document explicitly announces the 'Cancellation of subsequent repair offering' by Ultimovacs ASA. This action relates directly to a previously announced financing activity (the Private Placement and the intended Subsequent Offering). Among the provided categories, 'Capital/Financing Update' (CAP) is the most appropriate classification for announcements regarding fundraising, financing activities, or capital structure changes, even when the update is a cancellation of a planned offering.
2025-02-13 English
Financial calendar
Report Publication Announcement Classification · 100% confidence The document is titled 'Financial calendar' and lists future dates for key corporate events such as the 'Annual Report', 'Annual General Meeting', and various 'Quarterly Reports'. It does not contain the content of any of these reports, nor is it an announcement of a specific past event's results or a regulatory filing itself. It is a forward-looking schedule of corporate disclosures. Since there is no specific category for a 'Financial Calendar', and it is not an announcement of a report publication (RPA) but rather a schedule, the most appropriate fallback category is Regulatory Filings (RNS), as it is a mandatory disclosure regarding future reporting obligations.
2025-02-13 English
Ultimovacs ASA Reports Fourth Quarter 2024 Financial Results and Provides General Business Update
Interim / Quarterly Report Classification · 95% confidence The document is a 'Fourth Quarter 2024 Business Update and Financial Results' presentation for Ultimovacs ASA. It contains detailed financial tables (P&L, cash flow) for Q4 2024 and FY2024, alongside management commentary on business operations, M&A activity (business combination with Zelluna), and financial outlook. While it is presented in a slide-deck format, it provides substantive financial data and analysis for a specific quarterly period, fitting the definition of an Interim/Quarterly Report (IR). Q4 2024
2025-01-31 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.